Volume 10, Number 7—July 2004
Research
Nosocomial Infection with Vancomycin-dependent Enterococci1
Paul A. Tambyah*
, John A. Marx*, and Dennis G. Maki*
, John A. Marx*, and Dennis G. Maki*
Table
Clinical and epidemiologic features of patients with nosocomial enterococcal infections and uninfected control patientsa
| Features | VDE (n = 3) | VRE (n = 10) | Uninfected control patients (n = 10) |
|---|---|---|---|
| Age, y, mean ± SD |
39.0 ± 7.5 |
41.7 ± 20.2 |
51.1 ± 13.0 |
| Sex, no. |
|||
| Male |
0 |
5 |
7 |
| Female |
3 |
5 |
3 |
| Duration of hospitalization, days, mean ± SD |
41.7 ± 13 |
33.6 ± 12.1 |
37.6 ± 44.7 |
| ICU stay, days, mean ± SD |
9.3 ± 4.0 |
1.0 ± 1.9b |
7.4 ± 7.4 |
| Site of nosocomial enterococcal infection |
|||
| Primary bloodstream infection |
0 |
5 |
0 |
| Surgical wound infection |
1 |
2 |
0 |
| Intraabdominal infection |
1 |
1 |
0 |
| Urinary tract Infection |
1 |
1 |
0 |
| Service, no. |
|||
| Medicine or pediatrics |
1 |
5 |
5 |
| Surgery |
2 |
5 |
5 |
| Associated conditions, no. |
|||
| Malignancy |
1 |
4 |
2 |
| Diabetes mellitus |
2 |
3 |
4 |
| Renal failure |
3 |
3 |
4 |
| Trauma |
0 |
2 |
0 |
| Transplant recipient |
3 |
4 |
2 |
| APACHE II score, mean ± SD |
18.7 ± 2.1 |
15.1 ± 6.7 |
19.4 ± 10.0 |
| Serum creatinine, mg/dL, mean ± SD |
2.8 ± 0.5b |
1.5 ± 0.8 |
1.9 ± 1.8 |
| Days on antimicrobial agent |
|||
| Vancomycin |
27.3±13.7c |
9.1±10.3 |
5.7±7.6 |
| Aminoglycosides |
11.3±6.7 |
9.7±9.8 |
2.5±5.1 |
| First- or second-generation cephalosporins |
0.7±0.6 |
1.1±2.2 |
3.6±7.5 |
| Third-generation cephalosporins |
17.0±11.4d |
15.6±11.9e |
2.9±4.8 |
| Quinolones |
10.3±5.5 |
8.0±9.2 |
3.4±4.8 |
| Clindamycin |
2.3±4.0 |
7.1±11.7 |
1.2±3.8 |
| Metronidazole |
4.3±7.5 |
4.4±6.3 |
1.8±3.8 |
| Trimethoprim-sulfamethoxazole |
32.7±18.0d |
14.6±19.2 |
2.7±5.7 |
| Others |
1.0±1.7 |
5.6±9.5 |
4.8±9.6 |
| Total | 106.3±44.7d | 83.5±29.4e | 28.6±23.1 |
aVDE, vancomycin-dependent enterococci; VRE, vancomycin-resistant enterococci; ICU, intensive care unit; APACHE, Acute Physiology and Chronic Health Evaluation score.
bVRE vs. controls, p = 0.03.
cVDE vs. VRE, p = 0.02.
dVDE vs. VRE, p = 0.03.
eVDE vs. controls, p < 0.01.
fVRE vs. controls, p < 0.01.
1Presented in part at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 24–27, 1998.
Page created: January 27, 2011
Page updated: January 27, 2011
Page reviewed: January 27, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.